K562细胞RNA负载人树突状细胞后体外诱导特异性CTL的研究

目的探讨人的树突状细胞(dendriticcell,DC)体外经K562细胞株总RNA转染后,能否诱导出p210蛋白表达,并诱导特异性细胞毒T淋巴细胞(CTL)。方法自健康人浓缩白细胞制品(白膜)分离有粘附特性的单核细胞(PBMC),经GMCSF、IL4培养5d后,获得未成熟的DC(imatureDC,imDC);体外以脂质体DOTAP或直接电穿孔转染K562细胞总RNA。抽提转染前后以及转染24h后的DC内RNA进行RTPCR检测,Westernblot分析p210蛋白表达,以及诱导CTL杀伤K562细胞功能检测等。PBMC以每组5×106/ml,分别在不同组分的培养液中培养DC,通过细胞计数、流式细胞仪测定CD1a表达、细胞纯度来估计制备效果。结果RTPCR检测表明DC经K562总RNA转染后,细胞内出现BcrAbl的cDNA条带,24h后消失。Westernblot试验表明转染24h后,开始表达p210特征性蛋白;并且明显促进T细胞对K562的杀伤活性。1%自体血浆体积分数RPMI1640培养的DC的CD1a表达量最高,并且细胞获得数量也仅屈居第二,为总体评价较高的一组。结论应用肿瘤总RNA负载DC来制备DC疫苗具有可行性,预示改良的DC疫苗抗肿瘤的广泛应用前景。

In vitro induction of p210Bcr-Abl protein-specific cytotoxic T cell responses using 562 cell total RNA transfected human dendritic cells

Objective To investigate whether human monocyte-derived dendritic cells (DCs) can express p210 Bcr-Abl protein and induce antigen-specific CTL responses in vitro after transfection with total RNA of K562 cells (K562-RNA).Methods Immature DCs were derived from human peripheral blood monocytes after 5 day incubation in the presence of GM-CSF and IL-4. The cells were then transfected with K562-RNA using electroporation or DOTAP lipofection. To verify the successful transfection of DCs with K562-RNA, Bcr-Abl fusion gene expression was determined by RT-PCR and Western blot. The immune phenotypes of the DCs were analyzed by flow cytometry. CTL cytotoxicity was assayed by propidium iodide (PI) stain and flow cytometry. The amount of DCs, CD1a expression and purity of DCs were measured by FACS.Results Bcr-Abl fusion gene appeared in the DCs after transfection with K562 cell total RNA. But 24 hours later, the Bcr-Abl mRNA from the K562-RNA transfected DCs disappeared, while the cells were expressing p210 Bcr-Abl protein. The transfected DCs could significantly promote T lymphocytes to kill the target K562 cells. We found that PBMC can be induced to DC in culture medium containing human plasma, suggesting a potential for clinical application.Conclusion Human dendritic cells transfected by K562 total RNA can induce effective p210 Bcr-Abl protein-specific immune responses, which might broaden the spectrum of possible DC-based clinical applications.